CAMBRIDGE, UK--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures, today announced its cell therapy pipeline and declared its lead cell therapy candidate as it prepares to enter ...
Bio X Cell, the global leader of functional antibodies for in vivo and emerging preclinical models, unveils a refreshed brand identity which bridges nearly 30 years of scientific leadership in the ...
Footage captured inside the labs and clean rooms in Orca Bio's commercial manufacturing facility. "For transplant physicians, one of our greatest challenges has long been preserving the vital ...
The collaboration will evaluate Ajinomoto Group’s stem cell culture products using Syntax Bio’s programmable stem cell differentiation platform to support improved regenerative medicine discovery, ...
Three weeks ago, on January 5, Graphite Bio announced a voluntary pause of their Phase I/II CEDAR clinical trial of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) after observing ...
Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological Malignancies The approval of TREGZI, clinically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results